Prospective practice survey of management of cetuximab-related skin reactions

R. T. Lugtenberg*, C. B. Boers-Doets, P. O. Witteveen, C. M. L. van Herpen, A. N. M. Wymenga, J. W. B. de Groot, A. Hoeben, C. del Grande, B. van Doorn, J. J. Koldenhof, C. M. L. Driessen, H. Gelderblom

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Purpose Evidence-based guidelines on how to prevent or treat cetuximab-related skin reactions are lacking and multiple care and management strategies are used. The main purpose of the present study is to gain information about the different skincare products being used against skin reactions in metastatic colorectal cancer (mCRC) and recurrent/metastatic (R/M) or locally advanced (LA) squamous cell cancer of the head and neck (SCCHN) patients treated with cetuximab. Methods An open-label, prospective observational study conducted in the Netherlands. The occurrence of skin reactions and the care and management options taken were documented for 16 weeks, starting from the first administration of cetuximab. Results A total of 103 patients were included in 7 hospitals. 38 patients (37%) developed a grade >= 2 skin reaction. Eighty-six patients could be analysed for the primary endpoint (73.3% males, mean age 62.4 years, n = 44 LA SCCHN, n = 16 R/M SCCHN, n = 26 mCRC). The most frequently used skin products at some point during the observation period were moisturizing products (70%), systemic antibiotics (64%), topical antibiotics (58%), lipid-regenerating (28%) and other topical products (28%). The overall use of products gradually increased from baseline to week 6-10, reducing by week 16. Hospital protocols were the primary reason (> 50%) for choice of the skincare products and medications. Conclusion A variety of skin care products and antibiotics were commonly used. Only few patients developed severe cutaneous reactions. For patients, the occurrence of skin reactions did not influence their willingness to continue cetuximab therapy.

Original languageEnglish
Pages (from-to)3497-3506
Number of pages10
JournalSupportive Care in Cancer
Volume29
Issue number7
Early online date4 Nov 2020
DOIs
Publication statusPublished - Jul 2021

Keywords

  • Cetuximab
  • Skin reaction
  • Management
  • Head and neck cancer
  • Colorectal cancer
  • METASTATIC COLORECTAL-CANCER
  • QUALITY-OF-LIFE
  • PLUS CETUXIMAB
  • TOXICITY
  • TRIAL
  • HEAD

Cite this